LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "inhibitor" as a keyword



Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.

Sign Up to like & get
recommendations! Published in 2019 at "JAMA cardiology"

DOI: 10.1001/jamacardio.2019.1880

Abstract: Importance The antithrombotic treatment of patients with atrial fibrillation (AF) and coronary artery disease, in particular with acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), poses a significant treatment dilemma in clinical practice. Objective… read more here.

Keywords: inhibitor; analysis; p2y12 inhibitor; safety ... See more keywords
Photo by ldxcreative from unsplash

Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.

Sign Up to like & get
recommendations! Published in 2023 at "JAMA cardiology"

DOI: 10.1001/jamacardio.2023.1266

Abstract: Importance Clinical guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Nationwide adoption of SGLT2i for HFrEF… read more here.

Keywords: heart failure; inhibitor; therapy; heart ... See more keywords

Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.

Sign Up to like & get
recommendations! Published in 2023 at "JAMA dermatology"

DOI: 10.1001/jamadermatol.2023.0549

Abstract: Importance Tumor necrosis factor α (TNF) inhibitor-induced psoriasiform eruption is well recognized in adults, but few reports document this paradoxical effect in children. Objective To characterize the clinical features and the clinical time course of… read more here.

Keywords: tnf inhibitor; psoriasiform eruptions; inhibitor; eruption ... See more keywords

Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016

Sign Up to like & get
recommendations! Published in 2018 at "JAMA Internal Medicine"

DOI: 10.1001/jamainternmed.2018.0783

Abstract: Importance Current guidelines recommend prasugrel hydrochloride and ticagrelor hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). However, it is not well known how frequently these newer… read more here.

Keywords: iqr; inhibitor; p2y12; ticagrelor ... See more keywords
Photo by nci from unsplash

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.

Sign Up to like & get
recommendations! Published in 2020 at "JAMA network open"

DOI: 10.1001/jamanetworkopen.2019.20833

Abstract: Importance Because cancer drugs given in combination have the potential for increased tumor-cell killing, finding the best combination partners for programmed cell death 1 (PD-1) checkpoint inhibitors could improve clinical outcomes for patients with cancer.… read more here.

Keywords: combination; inhibitor; clinical trials; checkpoint ... See more keywords

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer

Sign Up to like & get
recommendations! Published in 2025 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2025.41648

Abstract: This systematic review and meta-analysis investigates the association of first-line poly(adenosine diphosphate-ribose) polymerase inhibitor (PARP inhibitor) maintenance therapy with efficacy and safety outcomes among patients with advanced-stage epithelial ovarian cancer. read more here.

Keywords: parp inhibitor; stage epithelial; first line; inhibitor ... See more keywords
Photo by bermixstudio from unsplash

Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP‐9 and MMP‐14

Sign Up to like & get
recommendations! Published in 2018 at "FEBS Letters"

DOI: 10.1002/1873-3468.13016

Abstract: MMP‐14 and MMP‐9 are two well‐established cancer targets for which no specific clinically relevant inhibitor is available. Using a powerful combination of computational design and yeast surface display technology, we engineered such an inhibitor starting… read more here.

Keywords: inhibitor; converting broad; mmp; timp2 ... See more keywords
Photo by niaid from unsplash

Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer

Sign Up to like & get
recommendations! Published in 2019 at "Molecular Oncology"

DOI: 10.1002/1878-0261.12582

Abstract: Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton‐interfering… read more here.

Keywords: inhibitor; testicular germ; germ cell; cell ... See more keywords

Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group

Sign Up to like & get
recommendations! Published in 2022 at "Molecular Oncology"

DOI: 10.1002/1878-0261.13340

Abstract: Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves the progression‐free rate compared… read more here.

Keywords: ribosome biogenesis; mtor inhibitor; inhibitor; endocrine therapy ... See more keywords

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK ‐fusion‐positive lung cancer

Sign Up to like & get
recommendations! Published in 2024 at "Molecular Oncology"

DOI: 10.1002/1878-0261.13746

Abstract: Cancers can develop resistance to treatment with ALK tyrosine kinase inhibitors (ALK‐TKIs) via emergence of a subpopulation of drug‐tolerant persister (DTP) cells that can survive initial drug treatment long enough to acquire genetic aberrations. DTP… read more here.

Keywords: cell; inhibitor; gpx4; bypass ... See more keywords

The dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice

Sign Up to like & get
recommendations! Published in 2018 at "FEBS Open Bio"

DOI: 10.1002/2211-5463.12498

Abstract: To clarify the effects of a dipeptidyl peptidase‐4 (DPP‐4) inhibitor on whole‐body energy metabolism, we treated mice fed a high‐fat diet (HFD) with teneligliptin, a clinically available DPP‐4 inhibitor. Teneligliptin significantly prevented HFD‐induced obesity and… read more here.

Keywords: inhibitor; teneligliptin; obesity; dpp ... See more keywords